{"id":3463,"date":"2026-10-21T16:35:38","date_gmt":"2026-10-21T08:35:38","guid":{"rendered":"http:\/\/www.atrintc.com\/blog\/?p=3463"},"modified":"2026-10-21T16:35:38","modified_gmt":"2026-10-21T08:35:38","slug":"how-do-these-policies-impact-the-chemical-medicine-industry-4f93-a7e3db","status":"publish","type":"post","link":"http:\/\/www.atrintc.com\/blog\/2026\/10\/21\/how-do-these-policies-impact-the-chemical-medicine-industry-4f93-a7e3db\/","title":{"rendered":"How do these policies impact the chemical medicine industry?"},"content":{"rendered":"

Over the past two years, as a chemical medicine supplier serving biotech startups and mid-sized pharma firms across North America and Europe, I\u2019ve spent countless late nights re-evaluating our operational playbook. It started with the Inflation Reduction Act (IRA) in the U.S.\u2014a policy that was meant to lower drug costs, but for someone who sources active pharmaceutical ingredients (APIs) from three contract manufacturers in India and Mexico, it felt less like a set of rules and more like a series of ripple effects that reshaped almost every part of our business. Today, I want to pull back the curtain on how these policies don\u2019t just affect big pharma\u2019s bottom line\u2014they trickle down to small suppliers like ours, and the lessons we\u2019ve learned might help others in the space prepare for what\u2019s next. Chemical Medicine<\/a><\/p>\n

<\/p>\n

First, let\u2019s cut through the noise around the IRA\u2019s most talked-about provision: the requirement that certain branded drugs negotiate prices with the Centers for Medicare & Medicaid Services (CMS) starting in 2026. At first, we thought this only impacted pharma companies that sell directly to hospitals and insurance providers. But here\u2019s what no one talks about: when a drug\u2019s price gets negotiated downward, the entire value chain adjusts to absorb that cut. We supply APIs for one of the first drugs to be included in the CMS negotiation pool\u2014a monoclonal antibody treatment for rheumatoid arthritis that our client started scaling production back in 2022, right as the IRA passed. Our original supply agreement was priced based on the drug\u2019s $3,500-per-bottle retail value. When CMS negotiated that price down to $1,800 last year, our client came to us and said, \u201cWe need a 30% reduction in your API cost\u2014otherwise, we can\u2019t keep sourcing from you.\u201d That wasn\u2019t a threat; it was a math problem. Their margins on the finished drug had shrunk so much that if we didn\u2019t lower our price, they\u2019d have to pass the cost to their patients or shut down production entirely.<\/p>\n

We couldn\u2019t just slash our costs, though. Our API is a highly complex molecule that requires specialized manufacturing, strict quality control, and years of regulatory validation. If we\u2019d cut corners on materials or testing, we\u2019d risk FDA audits, product recalls, or worse\u2014compromising patient safety, which is non-negotiable for us. Instead, we dug into our operations to find efficiencies we\u2019d missed in our pre-IRA days. We\u2019d been using three different shipping providers for raw material inputs because of minor timing differences, but we consolidated to one carrier that offered bulk discounts. We also switched to a more energy-efficient reactor in our production facility, which cut our electricity bills by 18% last quarter. These weren\u2019t one-time hacks; they were permanent changes that we\u2019d been putting off because they required upfront investment. The IRA forced us to act, and it worked\u2014we met our client\u2019s price reduction target without sacrificing quality.<\/p>\n

But the IRA isn\u2019t the only policy shifting the chemical medicine landscape. In the EU, the Pharmaceutical Strategy for Europe, adopted in 2020, has brought its own set of pressures, especially around \u201cstrategic autonomy\u201d for critical medicines. The goal here is simple: reduce the EU\u2019s reliance on non-EU API suppliers, which were handling 70% of the bloc\u2019s API needs pre-2020. For us, that\u2019s meant navigating new rules around local content requirements when we bid on EU-based supply contracts. Last year, we submitted a bid for a 50,000-liter API contract for a European generic drugmaker, and one of the key evaluation criteria was how much of the API\u2019s production happened within EU borders. Our largest manufacturing plant is in India, so we faced a big disadvantage compared to suppliers with EU-based facilities. But again, we found a way to adapt: we partnered with a small contract development and manufacturing organization (CDMO) in Germany to handle the final purification step of our API. That didn\u2019t just help us win the bid\u2014it also let us reduce shipping times for the finished API, from four weeks to 10 days, which is a win for both our client and their patients.<\/p>\n

What\u2019s interesting about both the IRA and the EU Pharmaceutical Strategy is that they were designed to benefit patients and national health systems, not small suppliers like us. But the policies\u2019 unintended consequences have created both risks and opportunities. On the risk side, we\u2019ve seen that regulatory changes can lead to sudden shifts in demand. For example, the IRA\u2019s provision to expand access to generic drugs has led to a 25% surge in demand for certain generic APIs over the past 18 months. We tried to ramp up production to meet that demand, but we hit a snag: many of our key raw material suppliers also faced capacity constraints because of the same surge. We ended up having to wait three months for a key chemical input, which pushed back our delivery schedules and cost us a couple of smaller client contracts. That\u2019s a common pain point for small suppliers: we don\u2019t have the bargaining power that big pharma has to lock in long-term raw material contracts, so we\u2019re at the mercy of supply chain volatility that policies often amplify.<\/p>\n

On the opportunity side, though, these policies have pushed us to invest in areas we\u2019d been hesitant to explore. For years, we\u2019d focused on making APIs for existing drugs, rather than investing in R&D for new chemical entities. But the IRA offers a 50% tax credit for manufacturers that produce API domestically in the U.S. for drugs covered under the negotiation program. We\u2019re currently working on a joint R&D project with a biotech startup in Boston to develop a more sustainable manufacturing process for a diabetes API. The tax credit from the IRA covers 40% of the project\u2019s costs, which makes it feasible for a small company like ours\u2014something we never would have been able to do without that policy incentive. Similarly, the EU\u2019s strategic autonomy goals have opened doors for us to form partnerships with European CDMOs, which has expanded our geographic reach and given us access to new markets we couldn\u2019t enter on our own.<\/p>\n

One lesson we\u2019ve learned through all this is that policy changes don\u2019t just impact big players\u2014they create a domino effect that starts with regulators and ends with small suppliers, and every part of the value chain has to adapt. Too often, when policy makers draft rules, they rely on input from large pharma companies and advocacy groups, not the small suppliers who are the backbone of API manufacturing. If they included more of us in the conversation, policies could be designed to reduce the burden on smaller firms, not just the big ones. For example, the IRA\u2019s price negotiation provision includes a \u201csmall manufacturer exception\u201d for drugs with limited production volumes, but that exception only applies to drugs under $500 per course. We work on drugs with much lower volumes but higher per-unit costs, which means we don\u2019t qualify for that exception. That\u2019s a gap policy makers could fix to help suppliers like us stay in business.<\/p>\n

Another key takeaway is that agility is no longer a nice-to-have\u2014it\u2019s a survival skill. Before these policies, we had a 5-year operational plan that barely changed. Now, we review our supply chain, pricing, and partnerships every quarter to stay ahead of new rule changes. We also prioritize building strong relationships with our clients, because when policy shifts create unexpected challenges, our clients are more willing to work with us to find solutions. That\u2019s something we\u2019ve focused on over the past two years: we don\u2019t just see ourselves as a supplier, but as a partner to the companies that rely on us. When our client faced a 30% price cut, we didn\u2019t just lower our price\u2014we shared our efficiency plans with them, so they understood how we were making it work. That transparency built trust, which has led to two additional supply contracts this year.<\/p>\n

<\/p>\n

Looking ahead, I know more policies are on the way. The U.S. is expected to expand the IRA\u2019s price negotiation program to more drugs in 2028, and the EU is set to finalize its updated API legislation next year. As a small chemical medicine supplier, I can\u2019t predict exactly how these policies will play out, but I can prepare. We\u2019re already mapping our current production processes to identify where we can reduce costs without sacrificing quality. We\u2019re also exploring additional partnerships with CDMOs in both the U.S. and EU to meet future local content requirements. Most importantly, we\u2019re advocating for policies that consider the needs of small suppliers, because if small suppliers thrive, the entire chemical medicine industry is more resilient.<\/p>\n

If you\u2019re a biotech startup, pharma company, or other industry partner looking for a reliable, quality-focused chemical medicine supplier, let\u2019s connect. We can walk you through our manufacturing processes, discuss how we can meet your supply needs, and work together to navigate the changing policy landscape.<\/h2>\n

Disinfectant<\/a> References<\/p>\n

    \n
  1. U.S. Department of Health and Human Services. (2023). Inflation Reduction Act: Drug Price Negotiation Program Overview.<\/li>\n
  2. European Commission. (2020). Pharmaceutical Strategy for Europe: Building a Stronger European Health Union.<\/li>\n
  3. International Society for Pharmaceutical Engineering. (2024). Global API Supply Chain Report: Volatility and Strategic Adaptations.<\/li>\n
  4. U.S. Internal Revenue Service. (2022). Tax Credits for Domestic Manufacturing of Generic Drugs and APIs.<\/li>\n
  5. European Federation of Pharmaceutical Industries and Associations. (2023). Strategic Autonomy in Pharmaceutical Manufacturing: Challenges for Small and Medium-Sized Suppliers.<\/li>\n<\/ol>\n
    \n

    Jiangxi Nuobang Biological Pharmaceutical Co., Ltd.<\/a>
    As one of the most professional chemical medicine manufacturers and suppliers in China, we also support customized service. Please rest assured to wholesale high quality chemical medicine in stock here from our factory. Welcome to contact us for quotation.
    Address: High-tech Zone, Jinxi County, Fuzhou City, Jiangxi Province, China
    E-mail: admin@tebangbio.com
    WebSite:     https:\/\/www.nuobangbio.com\/<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

    Over the past two years, as a chemical medicine supplier serving biotech startups and mid-sized pharma … How do these policies impact the chemical medicine industry?<\/span>Read more<\/a><\/p>\n","protected":false},"author":583,"featured_media":3463,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[3426],"class_list":["post-3463","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-industry","tag-chemical-medicine-4945-a81eec"],"_links":{"self":[{"href":"http:\/\/www.atrintc.com\/blog\/wp-json\/wp\/v2\/posts\/3463","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/www.atrintc.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.atrintc.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.atrintc.com\/blog\/wp-json\/wp\/v2\/users\/583"}],"replies":[{"embeddable":true,"href":"http:\/\/www.atrintc.com\/blog\/wp-json\/wp\/v2\/comments?post=3463"}],"version-history":[{"count":0,"href":"http:\/\/www.atrintc.com\/blog\/wp-json\/wp\/v2\/posts\/3463\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/www.atrintc.com\/blog\/wp-json\/wp\/v2\/posts\/3463"}],"wp:attachment":[{"href":"http:\/\/www.atrintc.com\/blog\/wp-json\/wp\/v2\/media?parent=3463"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.atrintc.com\/blog\/wp-json\/wp\/v2\/categories?post=3463"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.atrintc.com\/blog\/wp-json\/wp\/v2\/tags?post=3463"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}